Innoviva

About Innoviva

Innoviva is a Burlingame, California-based diversified biopharmaceutical holding company that manages a portfolio of royalty assets and directly develops and commercializes specialty therapeutics. Originally incorporated in 1996 as Advanced Medicine, Inc. and later operating as Theravance, Inc., the company took its current form in 2014 following a spin-off of its R&D operations and rebranded as Innoviva in 2016. The company operates across three primary divisions. Its royalty portfolio generates durable cash flows from respiratory products co-developed with GSK — most notably RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which are widely prescribed inhaled therapies for asthma and COPD. Through its wholly owned subsidiary Innoviva Specialty Therapeutics (IST), the company commercializes a growing portfolio of critical care and infectious disease products, including GIAPREZA (vasopressor for distributive shock), XERAVA (complicated intra-abdominal infections), XACDURO (hospital-acquired bacterial pneumonia caused by Acinetobacter), ZEVTERA (a next-generation cephalosporin antibiotic), and NUZOLVENCE (zoliflodacin, for uncomplicated gonorrhea — FDA-approved December 2025). The third division consists of strategic minority investments in healthcare assets, including Armata Pharmaceuticals (bacteriophage therapies), ImmunGene, Beacon BioSignals, and Syndeio Biosciences. Innoviva's business model combines the stability of royalty income with a high-growth specialty therapeutics platform, positioning it as a capital allocator in areas of high unmet medical need, particularly antimicrobial resistance (AMR). The company is listed on NASDAQ under the ticker INVA with a market capitalization of approximately $1.1–1.3 billion (2025).